Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.75 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ARG2 | P78540 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.48 |
| ▸ | TOP1 | P11387 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1436 | 1.00 | MAOB (0.75) | MAOBCA1CA2ARG2AOC3 | |
| Water SCHEMBL3478300 | 0.98 | MAOB (0.71) | MAOBCA1CA2ARG2AOC3 | |
| Hydrochloric Acid SCHEMBL5137799 | 0.98 | MAOB (0.71) | MAOBCA1CA2ARG2AOC3 | |
| SCHEMBL795584 | 0.93 | MAOB (0.65) | MAOBCA1CA2ARG2AOC3 | |
| SCHEMBL155055 | 0.87 | MAOB (1.00) | MAOBCA1CA2ARG2LOXL2 | |
| SCHEMBL1524697 | 0.87 | MAOB (1.00) | MAOBCA1CA2ARG2LOXL2 | |
| SCHEMBL155054 | 0.87 | MAOB (1.00) | MAOBCA1CA2ARG2LOXL2 | |
| SCHEMBL5489486 | 0.83 | MAOB (0.50) | MAOBCA1CA2ARG2AOC3 | |
| SCHEMBL5956337 | 0.81 | MAOB (0.68) | MAOBCA1CA2ARG2LOXL2 | |
| SCHEMBL3288071 | 0.78 | MAOB (0.62) | MAOBCA1CA2ARG2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951963-B2 | Process for preparing N-protected β-amino aldehyde compounds | THERAVANCE, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| WO-2003106399-A2 | PROCESS FOR PREPARING N-PROTECTED β-AMINO ALDEHYDE COMPOUNDS | THERAVANCE, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030233010-A1 | Process for perparing N-protected beta-amino aldehyde compounds | CUMBERLAND PHARMACEUTICALS INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030233010-A1 | Process for perparing N-protected beta-amino aldehyde compounds | DNPEP, PREP, ANPEP | MAOB 700/4885CA1 629/4885CA2 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.